| Title: |
The Frequency and Management of TP53 Mutation Carriers in Turkish Patients with BRCA-Negative Breast Cancer Under 50 Years of Age. |
| Authors: |
ÖZDEMİR, Taha Reşid1 dr.tahaoz@gmail.com, ÖZER KAYA, Özge1, EMİROĞLU, Mustafa2, ERDOĞAN, Kadri Murat1, DEĞİRMENCİ, Mustafa3, SAKA GÜVENÇ, Merve1, DEMİR, Gönül4, KOÇ, Altuğ1, ÖZYILMAZ, Berk1, KIRBIYIK, Özgür1 |
| Source: |
Turkish Journal of Oncology / Türk Onkoloji Dergisi. 2020, Vol. 35 Issue 2, p178-188. 11p. |
| Subject Terms: |
*BREAST tumor risk factors, *TUMOR suppressor genes, *BREAST tumors, *GENETIC counseling, *HEALTH care teams, *GENETIC mutation, *POLYMERASE chain reaction, *RISK assessment, *BRCA genes, *LI-Fraumeni syndrome, *SEQUENCE analysis |
| Geographic Terms: |
TURKEY |
| Abstract: |
OBJECTIVE Germline mutations in the TP53 gene cause Li-Fraumeni Syndrome (LFS). Breast cancer (BC) is the most common cancer that is seen in young women with LFS. The majority of BC in LFS occurs between 15 and 44 age of years. The present study aims to determine the frequency of TP53 gene germline mutation carriers in Turkish patients with BRCA-negative BC under 50 years of age as the first study from Turkey, to our knowledge, and to emphasize the importance of management in TP53 gene mutation carriers. METHODS One hundred patients with BRCA-negative BC younger than 50 years old were evaluated concerning mutations in the TP53 gene between 2016 and 2017 years. Sequencing analysis using targeted next-generation sequencing (NGS) and deletion/duplication analysis using multiplex ligation-dependent probe amplification (MLPA) method were performed in TP53 gene in all patients. RESULTS Five variants were identified in five of 100 patients (5%) in this study. Four of them were evaluated as known as pathogenic/likely pathogenic (4%; 4/100). One variant was evaluated as a variant of uncertain clinical significance (VUS). CONCLUSION The patients with BRCA-negative BC younger than 50 years old should be evaluated concerning TP53 gene mutations because of increased lifetime risk of various developing cancer. Appropriate genetic counseling should be given to patients with TP53 gene mutations, and the follow-up of these patients should be provided multidisciplinary. [ABSTRACT FROM AUTHOR] |
|
Copyright of Turkish Journal of Oncology / Türk Onkoloji Dergisi is the property of KARE Publishing and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
